ORCID Profile
0000-0001-5164-0436
Current Organisations
University of Limerick Kemmy Business School
,
Centro Hospitalar de Trás-os-montes e Alto Douro EPE
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
Innovative Business School Teaching
Publisher: Routledge
Date: 05-02-2014
Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients
Publisher: Elsevier BV
Date: 06-2018
DOI: 10.1016/J.JVIR.2018.02.004
Abstract: To evaluate the efficacy and safety of transarterial chemoembolization with polyethylene glycol (PEG) drug-eluting embolic agents in the treatment of hepatocellular carcinoma (HCC). A single-center retrospective study of 302 patients (258 men 85.4%) with HCC treated during a 20-month period was conducted. The mean patient age was 66 years ± 10 142 (47%) had Barcelona Clinic Liver Cancer stage A disease and 134 had (44.4%) stage B disease 174 (57.6%) had a single HCC tumor, 65 (21.5%) had 2, and 62 (20.9%) had 3 or more. Mean index tumor size was 36.6 mm ± 24.8. One-month follow-up computed tomography (CT) response per modified Response Evaluation Criteria In Solid Tumors and clinical and biochemical safety were analyzed. Progression-free and overall survival were calculated by Kaplan-Meier method. Median follow-up time was 11.9 months (95% confidence interval, 11.0-13.0 mo). One-month follow-up CT revealed complete response in 179 patients (63.2%), partial response in 63 (22.3%), stable disease in 16 (5.7%), and progressive disease in 25 (8.8%). The most frequent complications were postembolization syndrome in 18 patients (6%), liver abscess in 5 (1.7%), and puncture-site hematoma in 3 (1%). Biochemical toxicities occurred in 57 patients (11.6%). Survival analysis at 12 months showed a progression-free survival rate of 65.9% and overall survival rate of 93.5%. Patients who received transplants showed a 57.7% rate of complete pathologic response. Chemoembolization with PEG embolic agents for HCC is safe and effective, achieving an objective response rate of 85.5%.
Related Organisations
MedStar Georgetown University Hospital
Location: United States of America
Universidade Do Porto Instituto De Ciências Biomédicas Abel Salazar
Location: Portugal
University Of London
Location: United Kingdom of Great Britain and Northern Ireland
Centro Hospitalar De Trás-os-montes E Alto Douro EPE
Location: Portugal
Related Funding Activities
No related grants have been discovered for Sheila Killian.